The approval of pembrolizumab as an anti-PD-1 antibody in the 1st-line therapy for advanced/metastatic NSCLC with PD-L1 ≥ 50% (all histologies) provided direction for a new therapeutic option for patients with squamous cell carcinoma, accounting for approximately 25–30% of cases [82, 83]. This evidence concerns the gene CD274 and squamous cell carcinoma.